

ASX Release

Anatara Lifesciences Webinar and Q&A

Adelaide, 2nd December 2024: Anatara Lifesciences (ASX: ANR or “the Company”) is pleased to invite shareholders, investors and interested parties to an online Webinar presentation to discuss the Company’s:

- **Stage 2 Irritable Bowel Syndrome (IBS) Phase 2 clinical trial recruitment progress towards completion and Headline results readout, expected Q1 CY2025.**
- **New anti-obesity program, which focuses on GLP-1 agonism to develop a weight management product, that is complimentary to existing GLP-1 agonists in market and contemporary approaches.**
- **Share Purchase Plan which opened on 27th November 2024 and closes 18th December 2024.**

The webinar will be hosted by Chair, Dr. David Brookes and Dirk van Dissel, IR and Corporate Advisor, Candour Advisory.

A Company presentation released on the ASX today refreshes the recent Company progress consistent with announcements up to and including the AGM held on 14 November 2024. This presentation will be the reference document for the webinar this week.

The webinar will be held on Thursday 5th December at 10:30am AEDT / 10:00am ACDT / 7:30am AWST

For the Q&A session, participants are directed to use the Q&A function on Zoom with the questions to be answered at the end of the presentation segment.

Register for the webinar at the link below:

<https://us06web.zoom.us/j/86537777104>

Meeting ID: 865 3777 7104

After registering, you will receive a confirmation email containing information about joining the webinar. A recording will be available at the above link shortly after the conclusion of the live session.

Authorised by the Board of Anatara Lifesciences (ASX:ANR)



For more information please contact:

Dr. David Brookes

Chair, Anatara Lifesciences Ltd
+61 (0) 411 712 579
dbrookes@anatara.com

Dirk van Dissel

Candour Advisory – IR & Corporate Advisor
+61 (0) 408 326 367
dirk@candouradvisory.com.au

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based health products where there is significant unmet need. Anatara is focused on building a pipeline of human health products with a particular focus on conditions that involve the complexity of the gastrointestinal tract. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anatara Lifesciences Limited
Registered Office

C/-PERKS Level 8,81 Flinders Street, Adelaide SA 5000

Email info@anatara.com | Website anataralifesciences.com

